June 1, 2023
Philly Builds Bio+ Spring Reception, Philadelphia, PA

Philly Builds Bio+ Spring Reception:
State of the Life Science Market

The Post @ BioLabs
601 Walnut Street, Philadelphia PA 19106

In-Person Event
June 1, 2023 • 4:30 – 8:00 pm
Prices: $95 Members | $125 Non-Members

Builds Bio tour and event 2023

About the Event

After record years in 2020 and 2021, growth of the U.S. life sciences industry has returned to a more normal pace in 2023. Demand for lab/R&D space remains well above pre-pandemic levels. Life sciences employment reached a record high at the start of 2023, although the rate of growth slowed.  The state of the life science capital markets coupled with continued inflation and the uncertainties generated by recent banking failures have all had an impact on the state of the life science market. Nevertheless, the long-term outlook for life sciences is still healthy, marked by a strong focus on health and wellness, new therapies and advancements in technology.

This meeting examined the state of the market and future prospects, highlighting how companies are managing through a changing and uncertain time.

View Event Presentation (PDF)

Event Photo Gallery


4:30pm – 5:30pm     Tours of Philly BioLabs and IMVAX

5:30pm – 5:45pm     Check in and Networking

5:45 – 6:00pm     Welcome and Overview of the Meeting

  • Mitchel W. Simpler, Partner Emeritus, JBB, Founding Member and Steering Committee, Builds Bio+
  • Nancy J Kelley, President & CEO, Nancy J Kelley + Associates, Founding Member and Steering Committee, Builds Bio+

6:00pm – 6:45pm     State of the Life Science Market

  • Lauren Gilchrist, Executive Vice President and Market Leader, Newmark (Confirmed)
  • Joseph Fetterman, Executive Vice President, Colliers (Confirmed)
  • Ian Anderson, Senior Director of Research, CBRE (Confirmed)
  • Neil Brazitis, Senior Managing Director, Newmark (Confirmed)
  • Joseph Colletti, Executive Vice President, JLL (Confirmed)

6:45 – 7:30     The Company View

  • Eric Hacherl, COO, Kyttaro Therapeutics (Confirmed)
  • Sean Hemingway, COO, IMVAX (Confirmed)
  • Gwen Binder, President, Science and Technology, Cabaletta Bio (Confirmed)
  • Ken Locke, Vice President, Manufacturing and Supply Chain, Charisma Therapeutics (Confirmed)
  • Doug Carr, Senior VP and Head of Finance, Century Therapeutics (Confirmed)

7:30 – 8:00     Networking